JPRN-jRCT2080222249未知3 期
A Phase III Randomized Study of BBI608 and Best Supportive Care Versus Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •- Histologically confirmed advanced colorectal cancer that is unresectable.
- •- The only remaining standard available therapy as recommended by the Investigator is best supportive care.
- •- Must have presence of measurable disease as defined by RECIST 1.1.
- •- Must have an ECOG Performance Status of 0 or 1.
排除标准
- •- Major surgery within 4 weeks prior to randomization.
- •- Any known symptomatic brain metastases requiring steroids.
研究者
相似试验
进行中（未招募）
1 期
The aim of this study is to see how well an investigational drug (called BBI-608) works when it is given in combination with a standard anticancer treatment for people with advanced colon or rectal cancer.EUCTR2016-001627-31-BEBoston Biomedical, Inc.1,250
进行中（未招募）
1 期
The aim of this study is to see how well an investigational drug (called BBI-608) works when it is given in combination with a standard anticancer treatment for people with advanced colon or rectal cancer.Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic (Stage IV).MedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2016-001627-31-NLSumitomo Dainippon Pharma Oncology, Inc.1,250
进行中（未招募）
1 期
The aim of this study is to see how well an investigational drug (called BBI-608) works when it is given in combination with a standard anticancer treatment for people with advanced colon or rectal cancer.EUCTR2016-001627-31-ESBoston Biomedical, Inc.1,253
已完成
3 期
A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)Colorectal cancerbowel cancer10017991NL-OMON55360Boston Biomedical, Inc49
进行中（未招募）
1 期
The aim of this study is to see how well an investigational drug (called BBI-608) works when it is given in combination with a standard anticancer treatment for people with advanced colon or rectal cancer.Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic (Stage IV).MedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2016-001627-31-CZSumitomo Dainippon Pharma Oncology, Inc.1,250